Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of INCB099280 in immune checkpoint inhibitor-naive select solid tumors
2022-502716-37-00Phase 2Completed
- Sponsor
- Incyte
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of incb099280 in Nonhematologic neoplasms, sponsored by Incyte. Primary endpoints: Objective response rate, Incidence of treatment-emergent adverse events and 1 more. Started Sep 2023; status: completed.
02
Drugs
incb099280
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-502716-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502716-37-00.